TCGA-QK-A8ZA-01A-11R-A39I-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 0.084703196
- sex
- male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- SPERMATOGENESIS+0.330
- OXIDATIVE_PHOSPHORYLATION+0.290
- PROTEIN_SECRETION+0.280
- E2F_TARGETS+0.270
- PANCREAS_BETA_CELLS+0.270
- MYC_TARGETS_V1+0.230
- G2M_CHECKPOINT+0.220
- XENOBIOTIC_METABOLISM+0.190
- MTORC1_SIGNALING+0.170
- BILE_ACID_METABOLISM+0.130
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.520
- ANGIOGENESIS-0.480
- INTERFERON_ALPHA_RESPONSE-0.460
- ALLOGRAFT_REJECTION-0.450
- INTERFERON_GAMMA_RESPONSE-0.440
- INFLAMMATORY_RESPONSE-0.400
- TNFA_SIGNALING_VIA_NFKB-0.360
- MYOGENESIS-0.340
- APICAL_JUNCTION-0.330
- COAGULATION-0.330
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | fd49c74b-2a85-46cd-aaa0-dbd2f1284947 | — | — | 0.894 |
| 2 | R288 | — | — | 0.892 |
| 3 | SRR1516065 | — | — | 0.882 |
| 4 | SRR10900014 | — | — | 0.881 |
| 5 | TCGA-CR-6472-01A-11R-1873-07 | — | — | 0.881 |
| 6 | DRR168591 | — | — | 0.881 |
| 7 | R55 | — | — | 0.879 |
| 8 | SRR26320088 | — | — | 0.878 |
| 9 | R150 | — | — | 0.875 |
| 10 | 20040104.LumB | — | B | 0.871 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 17 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| SPERMATOGENESIS | 0.330 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.290 | Remibrutinib | — uncovered |
| PROTEIN_SECRETION | 0.280 | Remibrutinib | — uncovered |
| E2F_TARGETS | 0.270 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.270 | Cobimetinib | — uncovered |
| MYC_TARGETS_V1 | 0.230 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.220 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.190 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.170 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.130 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.120 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.060 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.060 | Remibrutinib | — uncovered |
| UV_RESPONSE_UP | 0.060 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.030 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.020 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.020 | Remibrutinib | — uncovered |